Last reviewed · How we verify
BOTOX®, Allergan
BOTOX blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary paralysis of muscles.
BOTOX blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary paralysis of muscles. Used for Cervical dystonia, Blepharospasm, Strabismus.
At a glance
| Generic name | BOTOX®, Allergan |
|---|---|
| Also known as | BOTOX |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Botulinum toxin type A |
| Target | SNARE proteins (specifically SNAP-25) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Dermatology, Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Botulinum toxin type A binds to presynaptic nerve terminals and cleaves SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins, preventing acetylcholine vesicles from fusing with the cell membrane. This results in temporary muscle paralysis lasting 3–4 months. The effect is reversible as the body gradually regenerates new nerve terminals.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Chronic migraine
- Hyperhidrosis
- Glabellar lines (cosmetic)
- Crow's feet (cosmetic)
Common side effects
- Headache
- Neck pain
- Injection site pain
- Muscle weakness
- Eyelid ptosis
- Dry mouth
- Flu-like symptoms
Key clinical trials
- Comparative Study Between Botulinum Toxin-A Injection and Shock Waves on Hypertrophic Scars in Hand-burned Children (NA)
- Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery (NA)
- BTX-A and Mirror Therapy for Chronic Stroke Spasticity (NA)
- Botulinum Toxin Injection in Hypercontractile Esophagus (PHASE2)
- Efficacy of an Intra-articular Injection of Botulinum Toxin A Associated With Splinting for Base-of-thumb Osteoarthritis (PHASE2, PHASE3)
- Botulinum Toxin Injection After Sternotomies to Improve Scar Aspect and Impact (PHASE3)
- Comparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity (PHASE2, PHASE3)
- Impact of OnabotulinumtoxinA (BOTOX®) on Stress (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BOTOX®, Allergan CI brief — competitive landscape report
- BOTOX®, Allergan updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI